Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Griswold Home Care is One of Franchise Dictionary Magazine’s 2020 Top 100 Game Changers


Franchise development is a top priority for Griswold Home Care, according to CEO Michael Slupecki.

“Franchise development is a top priority for Griswold Home Care,” said Griswold Home Care CEO Michael Slupecki. “We have some innovative incentives for franchise brokers and some top territories available for buyers. We are motivated for some real growth in the new year.”

Griswold Home Care is included in Franchise Dictionary Magazine’s 2020 Top 100 Game Changers. With more than 350,000 readers, Franchise Dictionary Magazine is a leading franchise publication in both digital and print format.

Targeting prospective franchisees in an informative and educational manner, Franchise Dictionary Magazine is well-respected throughout the industry. Being named a Game Changer is recognition of excellence in franchising.

“Franchise development is a top priority for Griswold Home Care,” said Griswold Home Care CEO Michael Slupecki. “We have some innovative incentives for franchise brokers and some top territories available for buyers. We are motivated for some real growth in the new year.”

Alesia Visconti is the CEO and Publisher of Franchise Dictionary Magazine. “Franchise ownership allows people to follow their dreams of being their own boss and taking control of their futures,” she said. “It supports people working for themselves but not by themselves. It’s a community of professionals all supporting successful business ownership. A brand that earns the Top 100 Game Changers designation raises the bar and clearly sets itself apart.”

For more information about the Franchise Directory Magazine’s 2020 Game Changers visit https://franchisedictionarymagazine.com/2020-game-changers/.

About Griswold Home Care

With 200 locations in 30 states, Griswold Home Care is one of the country’s top home care companies, delivering compassionate care 24/7 to its clients. Its purpose is to give people the help they need to live in the place they love. Through this purpose, Griswold Home Care helps adults maintain quality of life despite advanced age or onset of illness through services including companion care, home services, personal care, and respite care. Founded by the late Jean Griswold in 1982, the company has maintained its founder’s profound sense of empathy for older and disabled adults and those living with chronic conditions. For more information, visit http://www.griswoldhomecare.com or call 215.402.0200.

Share article on social media or email:

Sokörpe® Wins Best Hyaluronic Acid Serum Of 2020


Award-Winning Organic Hyaluronic Acid Serum from Sokörpe

Award-Winning Organic Hyaluronic Acid Serum from Sokörpe

Sokörpe’s® skincare products are truly revolutionary, pure, potent, and proven to work. Filled with natural, organic compounds, Sokörpe’s® skin and body products achieve unparalleled results without any toxins.

Sokörpe® the groundbreaking – genuinely natural – skincare line that combines innovative science with botanical wisdom won the US Beauty Innovation Award for its Hyaluronic Acid Serum on October 12, 2020. The judges declared Sokörpe’s® Hyaluronic Acid Serum ‘Best Anti-Blemish Product of the Year’.

Sokörpe® Cosmeceuticals’ Hyaluronic Acid Serum is nonirritating and promotes healthier, more supple skin, speeds up wound healing, caused by acne and pimples, firms the skin around the eye area, increases moisture to get rid of puffiness, and softens fine lines on the rest of the face. It protects against sun damage, reduces large pores, and regulates oil; it also minimizes redness and blotchiness. Sokörpe’s® Hyaluronic Acid Serum is a powerful and critical humectant that binds water to collagen.

Many skin-care brands use pure Hyaluronic acid – as it is cheaper to generate. Sokörpe’s® Hyaluronic Acid Serum is made from Sodium Hyaluronate, which is the sodium salt of Hyaluronic acid and has a much smaller molecular size than Hyaluronic Acid, causing it to easily penetrate the skin’s surface and reaching deeper levels, thereby truly reducing the signs of aging through increased nutrient absorption. Sokörpe’s® Hyaluronic Acid Serum can retain a relatively large amount of water — up to 1,000 its own weight. Sokörpe® forms Sodium Hyaluronate biotechnologically through microbial fermentation of yeast extract.

Sokörpe’s® Hyaluronic Acid Serum is then infused with Niacinamide (Vitamin B3), Panthenol (Provitamin B5), organic MSM and hygroscopic Sodium PSA, assuring 7 skin benefiting amino acids and 5 chelated essential minerals – zinc, silicon, magnesium, copper and iron derived from the yeast of Saccharomyces Cerevisiae, are transported into the deep layers of the skin to work their magic.

Other ingredients include organic Aloe Vera juice, organic Bulgarian rose distillate, organic Witch Hazel extract, organic blue agave BioFerment, watermelon BioFerment, white truffle, algae and hydrolyzed rice protein.

Sokörpe’s® Hyaluronic Acid Serum contains a potent 1.5% of organic Sodium Hyaluronate.

Sokörpe’s® Hyaluronic Acid demulcent is 70% organic, oil and silicone free and cold processed.

About Sokörpe®

Sokörpe’s® skincare products are truly revolutionary, pure, potent, and proven to work. Filled with natural, organic compounds, Sokörpe’s® skin and body products achieve unparalleled results without any toxins. No other commercially produced product comes even close to the quality and care placed into Sokörpe’s® line of skincare products.

Sokörpe’s® serums, formulations, creams, and ointments are the result of continuous plant-based science with renowned phytologists, constantly improving formulations by discovering and incorporating new, premium botanicals and medicinals.

Sokörpe’s® skincare products are cruelty-free, vegan. The products are also free of fragrances – unless otherwise specifically noted.

Sokörpe® is headquartered in the greater Miami metropolitan area.

Share article on social media or email:

Babyscripts Announces New Funding Through Strategic Partner Program


News Image

This investment is validation that health systems see the value of our solution — and they’re willing to put their money on it.

Babyscripts, the leading virtual care platform for managing obstetrics, today announced a new round of investments through their Strategic Partners Program, a unique investment bloc composed of health systems interested in forwarding Babyscripts’ cutting-edge digital solutions for pregnant populations. Partners include Phoenix-based Banner Health, one of the largest nonprofit health care systems in the country; the CU Healthcare Innovation Fund, located on the University of Colorado Anschutz Medical Campus in Aurora, Colorado; the Froedtert & the Medical College of Wisconsin health network, an integrated health care system based in Wisconsin; and WellSpan Health, an integrated health system serving central Pennsylvania and northern Maryland.

This investment round is structured to leverage the input and support of clinical and health system partners, ensuring that Babyscripts’ product development and future roadmap aligns with customer needs.

“From the beginning, we’ve set ourselves apart from other tech companies by partnering with physicians to make sure that we’re developing solutions that will actually be useful and improve outcomes, not just look and feel ‘cutting-edge’,” said Juan Pablo Segura, co-founder and President of Babyscripts. “This investment is validation that health systems see the value of our solution — and they’re willing to put their money on it.”

“We believe the future of healthcare is combining virtual patient management and remote monitoring technologies in ways that increase access and improve outcomes at lower cost,” said Steven Lindseth, General Partner, CU healthcare Innovation fund, “Babyscripts has perfected this model against the societal imperative to improve maternal health, a mission that we can all agree is critical to fixing US healthcare.”

The majority of the investors are current customers of Babyscripts, uniquely qualifying them to offer support and demonstrating their confidence in the company’s value.

“Banner is proud to invest in Babyscripts’ highly innovative offerings for virtual maternity care, which we hope to scale across our six-state system,” said Scott Nordlund, chief strategy and growth officer at Banner Health and head of Banner Innovation Group. “Central to our innovation strategy are partners like Babyscripts, with whom we can tailor streamlined digital solutions for our patients to make health care better, simpler, and easier to access.”

“We know that meeting our patients where they are and connecting in a personal and meaningful way outside of the clinic walls can improve the health and well-being of expectant moms and their babies,” said Michael L. Anderes, FACHE, chief innovation and digital officer, Froedtert & the Medical College of Wisconsin health network.

“Our partnership with Babyscripts began in response to what we hear from new moms,” said Megan Lecas, Senior Vice President of Service Lines at WellSpan Health. “They want greater access, more convenience, healthier outcomes and fewer appointments when appropriate. Babyscripts complements the expert care provided by our women’s health team while providing more flexibility for consumers.”

Babyscripts has spent the last six years building a clinically-validated, virtual care platform to allow OBGYNs to deliver a new model of prenatal care. Using internet-connected devices for remote monitoring, Babyscripts offers risk-specific experiences to allow providers to manage up to 90% of pregnancies virtually, allowing doctors to detect risk more quickly and automate elements of care.

About Banner Health

Headquartered in Arizona, Banner Health is one of the largest nonprofit health care systems in the country. The system owns and operates 30 acute-care hospitals, two rehabilitation hospitals, Banner Health Network, Banner – University Medicine, academic and employed physician groups, long-term care centers, outpatient surgery centers and an array of other services; including Banner Urgent Care, family clinics, home care and hospice services, pharmacies and a nursing registry. Banner Health is in six states: Arizona, California, Colorado, Nebraska, Nevada and Wyoming. For more information, visit bannerhealth.com.

About The CU Healthcare Innovation Fund

The CU Healthcare Innovation Fund is located on the University of Colorado Anschutz Medical Campus in Aurora, Colorado. The fund invests in companies that have developed meaningful partnerships with the institutions on the campus. The $50 million fund invests across digital health, therapeutics and devices. For more information visit http://www.cuvcfund.com

About Froedtert & the Medical College of Wisconsin

The Froedtert & the Medical College of Wisconsin regional health network is a partnership between Froedtert Health and the Medical College of Wisconsin supporting a shared mission of patient care, innovation, medical research and education. Our health network operates eastern Wisconsin’s only academic medical center and adult Level I Trauma Center at Froedtert Hospital, Milwaukee, an internationally recognized training and research center engaged in thousands of clinical trials and studies. The Froedtert & MCW health network, which includes five hospitals, one of which is a nationally ranked academic medical center, more than 1,600 physicians and nearly 40 health centers and clinics, draws patients from throughout the Midwest and the nation. In our most recent fiscal year, outpatient visits exceeded 1.1 million, inpatient admissions to our hospitals were 49,250 and visits to our network physicians totaled 932,000. For more information, visit froedtert.com.

About WellSpan Health

WellSpan Health is an integrated health system that serves the communities of south central Pennsylvania and northern Maryland. The organization includes a clinically integrated network of approximately 2,600 physicians and advanced practice providers (APPs), including more than 1,600 employed physicians and APPs; a regional behavioral health organization; a home care organization; eight respected hospitals; approximately 20,000 employees; and more than 200 patient care locations. WellSpan is a charitable, mission-driven organization, committed to exceptional care for all, lifelong wellness and healthy communities. Visit WellSpan.org.

About Babyscripts

Babyscripts is delivering a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their healthcare providers. We’ve spent the last six years delivering the most-implemented mobile clinical solution for remote monitoring in pregnancy, with the mission to eliminate maternal mortality and improve access to care for all mothers. Babyscripts was named to the 2020 Digital Health 150, CB Insights’ annual ranking of the 150 most promising private digital health companies in the world. For more information on our virtual care solution and to request a demo, visit http://www.babyscripts.com.

Redirect Health Creates Cost-Effective Healthcare Program for Canadian Snowbirds


News Image

“Canadian snowbirds increasingly need their healthcare to be portable, easy, and affordable. No one should have to worry about having access to quality care when they come to Arizona,” said Paul Johnson, CEO and co-founder of Redirect Health.

As COVID-19 cases and hospitalizations continue to reach meteoric heights across the U.S., one Arizona-based healthcare firm, Redirect Health, is providing a cost-effective and efficient solution to healthcare for Canadian snowbirds and travelers visiting the U.S.

The new Canadian Snowbird program offers individuals access to high-quality healthcare while avoiding unnecessary costs, providing peace of mind during these turbulent times.

The program allows members to schedule and fast track virtual and in-office appointments with no out-of-pocket costs, as well as coordinate discounted prescription refills, x-rays, COVID-19 testing plus treatments and more through call, text, or video, 24/7. The Canadian Snowbird program also features referral and personalized care navigation and cost negotiation to help guide members through the U.S. healthcare system. On top of this, the program offers physician-to-physician case management to provide important communication between U.S. physicians and Canadian physicians.

“The pandemic has further highlighted the need for all individuals to have access to quality care, without surprise bills or unnecessary costs,” said Dr. Janice Johnston, medical director and co-founder of Redirect Health. “As a Canadian myself, I understand that Canadians need the comfort of knowing they can receive proper medical care when they are away from home.”

Membership includes no cost access to 24/7 virtual primary care, primary care office visits, routine lab work, and chiropractic office visits at Redirect Health’s three Maricopa County medical centers. It also includes access to a prescription discount program, discounted imaging, hospitalization and catastrophic protection, and emergency travel back to Canada.

“Canadian snowbirds increasingly need their healthcare to be portable, easy, and affordable. No one should have to worry about having access to quality care when they come to Arizona,” said Paul Johnson, CEO and co-founder of Redirect Health. “Our program offers a cost-effective solution for Canadians that avoids the unnecessary stress of getting medical attention for everyday or emergency situations.”

The Canadian Snowbird program is $12.99 per day for individuals, $19.99 per day for a couple, and $29.99 per day for a family membership.

“Canadians rent or own about 100,000 homes in Arizona and, even with COVID-19, many are still making their way down here this winter,” said Glenn Williamson, CEO of Canada Arizona Business Council. “Now more than ever, it’s important for them to have a healthcare option that is affordable and offers so much.”

For more information about Redirect Health, please visit https://www.redirecthealth.com/canada/

###

ABOUT REDIRECT HEALTH

Redirect Health is a Scottsdale-based direct care provider and advocate for small business — the result of over 20 years of innovative work in healthcare with a focus on putting people, and the businesses that employ them, first. Dr. David Berg, Dr. Janice Johnston and, past-Phoenix mayor, Paul Johnson started Redirect Health with a goal to simplify healthcare and lower costs.

Simply removing waste, unnecessary administration and streamlining care created a huge positive change that has allowed Redirect Health to grow exponentially, and now offer services across the country. By pushing back on the traditional healthcare system, Redirect Health has put the focus back on people and away from billing codes, copays and unnecessary use of hospital care. Redirect Health now serves over 11,000 people and has a staff of over 200 employees.

The Redirect Health model is so effective, the company not only offers free healthcare to all their employees and families, but they help companies all over the nation do the same. This unique offering gives companies an advantage in the job market for both recruiting and retaining quality employees.

Share article on social media or email:

GHX Promotes Chris Batson to Chief Financial Officer


Chris Batson, CFO, Global Healthcare Exchange

I’m confident Chris will help us continue to navigate the ripple effects of COVID-19 and deliver on our mission to enable better patient care and help the healthcare community save more than a billion dollars each year.

Global Healthcare Exchange (GHX) today announced the promotion of Chris Batson to Chief Financial Officer, effective January 1, 2021. Batson, who has served since 2019 as GHX’s vice president, Finance and Accounting, will succeed Rob Gillespie in the role of CFO. Gillespie will continue with the company until the summer of 2021 to ensure a seamless transition. Batson will report directly to CEO Bruce Johnson.

“Rob’s impact at GHX the past thirteen years cannot be overstated,” said Johnson. “I’m grateful for the care he’s put into developing a solid transition plan and his ongoing partnership. Rob has helped our company evolve alongside the industry and create considerable value for our customers and equity holders. On behalf of our Board and everyone at GHX, I’d like to thank Rob and wish him continued success.”

Batson brings extensive experience in general management, business strategy, mergers and acquisitions, capital structure management and private and public company management. In his earlier role at GHX, Batson was responsible for the company’s Financial Planning & Analysis, Treasury, Tax, Audit, Financial Reporting and Controllership functions.

“Since Chris joined GHX more than a year ago, I’ve been impressed by his curiosity, work ethic, passion for our customers and colleagues and skill in solving complex challenges,” added Johnson. “Having previously served in senior business and CFO roles, Chris brings a well-rounded perspective of GHX’s financial needs as well as P&L leadership. I’m confident Chris will help us continue to navigate the ripple effects of COVID-19 and deliver on our mission to enable better patient care and help the healthcare community save more than a billion dollars each year.”

“As value-based care becomes the norm and we move toward the creation of more resilient, clinically integrated supply chains, GHX is perfectly poised to support the industry’s transformation,” said Batson. “I’m excited to solidify our long-term vision during an important industry evolution.”

Prior to joining GHX, Batson served as president for ACS Group, a privately held $600 million information technology consulting and staffing company. He also served as senior vice president and general manager, and earlier as CFO, at Ciber Inc., a global information technology consulting, services and outsourcing company. Batson has also served in senior business and finance roles at organizations including TeleTech Holdings and NCR Corporation. Batson has a BS in Industrial Engineering from the University of Tennessee and an MBA from Indiana University’s Kelley School of Business.

About GHX

Building on decades of collaboration between providers, manufacturers, distributors and other industry stakeholders, Global Healthcare Exchange, LLC (GHX) is leading the charge in helping organizations run the new business of healthcare. By automating key business processes and translating evidence-based analytics and data into meaningful action, GHX is helping the healthcare ecosystem to move faster, operate more intelligently and achieve greater outcomes. With the support of GHX, healthcare organizations have removed billions of dollars of wasteful healthcare spend. For more information on GHX’s suite of world-class, cloud-based supply chain and pharmacy solutions, visit http://www.ghx.com and The Healthcare Hub. GHX has also launched a COVID-19 Information Center that provides a wealth of free resources and access to data and information needed to help serve patients and protect staff during the pandemic.

Share article on social media or email:

Spry Therapeutics Partners with Healthcare Surfaces Institute to Mitigate the Spread of Healthcare Acquired Infections


Spry Pure PPE Pillow with Pneumapure filter technology

Spry’s goal has always been to protect patients and caregivers with our breathable barrier solution, and we look forward to bringing soft-surface cleanliness to the forefront of prevention.

Spry Therapeutics and Healthcare Surfaces Institute today announced they have entered into a strategic partnership, combining the organization’s clinical expertise and resources with Spry’s deep knowledge in soft-surface contamination – particularly as it pertains to pillows and mattresses. With surfaces playing an increasingly critical role in the fight against healthcare acquired infections (HAIs), both parties recognize the importance of including soft-surface contamination in the discussion around prevention.

Soft surfaces – such as pillows and mattresses – can facilitate the transfer of disease within hospitals, with deadly infections spreading from patient to patient. In fact, ECRI Institute listed soft surfaces second on their list of Top Health Technology Hazards, stating: “Blood and other body fluids that remain on, or within, mattresses or mattress covers after cleaning can contact subsequent patients, posing an infection risk.”

Spry Therapeutics is committed to helping healthcare facilities eliminate soft surfaces as vectors for contamination by providing the world’s first and only soft-surface filter technology: Pneumapure. The company’s patented filter technology is proven effective in blocking even the smallest “superbugs” – down to .02 micron – from entering or exiting any soft surface to which it’s applied, helping to prevent the transmission of deadly diseases among patients and caregivers. Pneumapure also reduces costs associated with HAIs from environmental impact to disposal costs, annual purchase expenditures and more.

The company’s partnership with Healthcare Surfaces Institute is based on the fundamental understanding that many HAIs are preventable when the problem is understood and proper guidelines, testing and infection prevention protocol are implemented. The Institute is a collaboration of key decision makers in healthcare, manufacturing, academia, professional organizations, standards-setting organizations, regulatory agencies and other nonprofit entities. Each of these specialists is focused on scientific research and creating measures, metrics, and guidelines, as well as outreach and educational programs to reduce preventable infections by interrupting transmission of microbes via surfaces.

“We are thrilled to be partnering with Healthcare Surfaces Institute in their mission to reduce the spread of infection through surfaces,” says Bill Purdy, CEO and Co-Founder of Spry Therapeutics. “From inception, Spry’s goal has always been to protect patients and caregivers with our breathable barrier solution, and we look forward to bringing soft-surface cleanliness to the forefront of prevention.”

“We are really looking forward to including Bill and his team in our certification initiative work,” says Linda Lybert, Founder and Executive Director of Healthcare Surfaces Institute. “He brings incredible expertise around the issues facilities face with soft surfaces, specifically pillows and mattresses. Patients are constantly in direct contact with these surfaces, and we need to make sure they can be effectively cleaned and disinfected. Bill will also become a resource to our Scientific Advisory Board and will participate in development of research and guidelines with others in the field.”

To learn more about Spry Therapeutics and its fight against HAIs with its virus-blocking filter technology, visit sprytx.com.

About Spry Therapeutics

Spry Therapeutics is a health and wellness technology company that uses a proprietary soft-surface filter technology to block all pathogens from entering or exiting any soft surface to which it’s applied. The Company’s Pneumapure® filter is designed to help prevent cross-contamination among patients and caregivers, and provide a clean sleep solution to businesses and consumers alike. Spry Therapeutics is headquartered in White Plains, NY. For more information, visit sprytx.com. Follow Spry Therapeutics on LinkedIn.

About Healthcare Surfaces Institute

The Healthcare Surfaces Institute is a cutting-edge collaboration of thought leaders who work together to evaluate and understand all aspects of the role surfaces play in transmitting pathogens that cause infection and illness in healthcare settings.

Finding solutions to the spread of infections via surfaces requires an understanding of all contributing factors. This can only be done by bringing together experts that have high levels of understanding and expertise in many different areas – often with very different perspectives and opinions about how the issue must be addressed.

Our mission is to reduce preventable infections through collaboration of industry, academia, science, regulatory, and service sectors by interrupting the transmission of surface-related pathogens in healthcare in support of community and public health.

Share article on social media or email:

Survey Finds On-Site Inspections of Device Makers have Plummeted by 93% as FDA Scrambles To Find Virtual Solutions


https://www.greenlight.guru/

“Quality isn’t a department, but a cultural mindset within a business. Quality cannot be treated as a check-the-box activity — unfortunately, even when mandated by law, we’re seeing companies do the bare minimum.”

Greenlight Guru, the only medical device quality management system (MDQMS) software platform, today announced findings from the “State of Medical Device Product Development & Quality Management Report 2021.” The original research report reveals new insights from survey findings of over 300 medical device product development and quality professionals from around the world, providing the global medical device community with insights into current strategies, tactics, and technologies being used to accelerate product development, ensure compliance, and prioritize quality.

One of the more striking findings of this study is the gap between executives and front-line managers on the risks their organization faces related to quality. Executives are far more likely than managers and individual contributors to give their company high marks for quality management and are less concerned about the risks posed by poor quality management. Behind the scenes, however, their front-line workers are feeling growing concerns over key regulations as well as their company’s quality improvement plans for the coming year.

The current health crisis revealed insights that suggest a new catalyst for quality improvement has emerged despite the many obstacles organizations are facing. Findings show that two thirds of respondents work for companies that don’t share a uniform commitment to prioritizing quality as a strategic asset, resulting in core misalignment across departmental roles.

“To find that more than 80 percent of organizations are asking their quality and engineering teams to ‘make do’ with legacy tools and solutions is an eye-opener,” said David DeRam, CEO of Greenlight Guru. “Quality isn’t a department, but a cultural mindset within a business. Quality cannot be treated as a check-the-box activity — unfortunately, even when mandated by law, we’re seeing companies do the bare minimum.”

Additional findings from the report identified varying responses by organizations in dealing with the COVID-19 pandemic, which has buoyed revenue growth for medical device companies (79 percent) due to spikes in demand, while it has threatened financial viability for other organizations (39 percent) and wreaked havoc on supply chain systems.

Some other striking statistics from the report include:


  • Non-competitive companies are 71% more likely to struggle to keep up with regulatory changes than more competitive organizations.
  • Medical device companies who leverage an industry-specific QMS are 67% more likely to be able to demonstrate closed loop traceability than those who use general-purpose tools for quality management.
  • Highly-competitive organizations are twice as likely to increase their investment in quality management in 2021 than their less competitive counterparts.

Results from the State of Medical Device Product Development & Quality Management Report 2021 were driven from an online survey that was fielded between October 6 and October 20, 2020. Survey respondents consisted of 311 participants, of whom are employed in engineering, quality, regulatory, and operational roles by device organizations ranging in size from small to enterprise level that are located in various regions around the world.

To download the full State of Medical Device Product Development & Quality Management Report 2021, please visit https://www.greenlight.guru/state-of-medical-device.

About Greenlight Guru

Greenlight Guru is the only quality management software platform designed specifically for medical device companies. The platform helps companies bring safer products to market faster, simplifies FDA and ISO regulatory compliance and provides a single source of truth by connecting the management of all quality processes like CAPAs, risk, audits and more. Greenlight Guru’s platform is used by thousands of users across the globe to push beyond baseline compliance and achieve True Quality for their medical devices. For more information, visit http://www.greenlight.guru.

Media Contact

Kate Johnson

kate_johnson@blastmedia.com

(317) 806-1900

Share article on social media or email:

A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics, Upcoming Webinar Hosted by Xtalks


To enable sensitive variant detection across 20,000 genes, this enhanced exome assay and chemistry achieves high sequencing depth of approximately 2,000x exome-wide, with additional boosted depth, 5,000x, for 247 cancer-related genes.

While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies and multi-region tissue sampling has demonstrated that there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. NeXT Liquid Biopsy™, a first-of-its-kind, high-performance, exome-wide liquid biopsy assay, is designed to complement ImmunoID NeXT™, providing a unique ability to further evaluate the cancer ecosystem and advance the development of next-generation therapies.

NeXT Liquid Biopsy enables investigation into key applications, such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. NeXT Liquid Biopsy is purpose-built to navigate the inherent variability of circulating tumor DNA (ctDNA), elucidating key areas of tumor biology not often addressed by targeted, commercially available liquid biopsy panels.

To enable sensitive variant detection across 20,000 genes, this enhanced exome assay and chemistry achieves high sequencing depth of approximately 2,000x exome-wide, with additional boosted depth, 5,000x, for 247 cancer-related genes. Personalis has developed a computational pipeline optimized to lower the noise floor for variant detection, providing sensitive monitoring and de novo detection of variants over multiple time points.

Join expert speakers from Personalis, Sean Michael Boyle, PhD, Senior Director, Bioinformatics Applications; and Dan Norton, MBA, Senior Product Manager, in a live webinar on Thursday, December 17, 2020 for a discussion of the data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of various reference standards and actual patient samples. Participants can choose from 2 live broadcasts at 8am EST (1pm GMT/UK) and 4pm EST.

For more information, or to register for this event, visit NeXT Liquid Biopsy: A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Amplify Surgical®, Inc. Announces First Surgical Case with 12-Degree Hyperlordotic dualX® Dual Expanding Interbody Fusion Implant


Amplify Surgical, Inc., a medical device company focused on innovative dual-expanding technology for the lumbar spine, is excited to announce the launch of the dualX T/PLIF 12-Degree hyperlordotic interbody cages. Dr. Nima Salari, MD, FAAOS, from Scottsdale AZ, became the first spine surgeon to implant the new hyperlordotic dualX interbody cage, a TLIF spacer that provides additional lordosis. The minimally invasive procedure was recently performed at Honor Shea Health, one of Arizona’s leading hospitals and healthcare networks.

The hyperlordotic implants developed for the TLIF procedure are the company’s latest innovative advancement in an effort to improve sagittal plane correction. The implants developed for TLIF procedures offer a 12-degree hyperlordotic footprint in dualX T/PLIF implants and designed to improve sagittal balance restoration capabilities.

“Offering my patients the benefit of smaller incisions and less exposure to potential complications is why I specialize in minimally invasive surgery,” said Dr. Nima Salari. “For this TLIF procedure, I needed to fuse L5/S1 posteriorly due to anterior vascular anomalies. The broad footprint and 12 degrees of lordosis provided a similar advantage to an ALIF through a posterior approach.”

“The launch of dualX 12-Degree option demonstrates our commitment to improving patient outcomes by commercializing innovative solutions that accommodate the need for increased lumbar lordosis. We look forward to providing more implant options in the near future,” said Andy Choi, CEO of Amplify Surgical.

About Amplify Surgical, Inc.

Amplify Surgical is a privately held spinal device company located in Laguna Hills, CA. The Company focuses on developing and commercializing innovative and minimally invasive technologies for spine surgery. Amplify Surgical is a portfolio company of IntuitiveX, a life science innovation incubator.

Contact:

Andy Choi, CEO

Amplify Surgical, Inc.

info@amplifysurgical.com

765-AMPLIFY

Share article on social media or email:

METAvivor and Ciitizen Announce Partnership and New Clinical Trial Search Tool


News Image

Metavivor is thrilled to partner with ciitizen to bring this multi-layered clinical trial search tool to the metastatic breast cancer community. It will help patients narrow down their options for the latest clinical trials and personalize them to their diagnosis

Metavivor Research and Support Inc., a national non-profit organization dedicated to funding research for stage IV metastatic breast cancer (MBC), announced a strategic partnership with consumer health tech company Ciitizen to bring a comprehensive new Clinical Trial Search Tool and Clinical Trial Matching Program to the stage 4 metastatic breast cancer community.

Metavivor took up the mantle for increased clinical trials in 2017 and since that time has been on a mission to improve clinical trials and encourage patient participation. During this time, the organization discovered that trial searches were lacking information or did not connect the right trial to the patients’ particular metastatic breast cancer. With the help of Ciitizen, Metavivor can now offer clinical trial search and matching service options to those living with MBC. To transition metastatic breast cancer so that it is no longer a death sentence; increased research investment and participation in clinical trials is desperately needed. Metavivor is a leader on both sides of the equation: funding metastatic breast cancer research and empowering the metastatic breast cancer community to participate in critical research.

“No one dies from a tumor that remains in the breast, it is only when the cancer cells spread beyond the breast and metastasize to other organs in the body that breast cancer becomes fatal,” said Metavivor Board President, Jamil Rivers. “Metastatic or stage 4 breast cancer research has been woefully underfunded for a long time. We have to give new treatments a chance, so people with metastatic breast cancer can live longer. Clinical trials are our key to finding life extending treatments.”

Clinical trials are a key component in advancing medical treatment in cancer and in particular metastatic cancer. “Metavivor is thrilled to partner with Ciitizen to bring this multi-layered clinical trial search tool to the metastatic breast cancer community. It will help patients narrow down their options for the latest clinical trials and personalize them to their diagnosis,” said Rivers. Participating in a trial can also afford patients access to high-quality care and new treatments. A recent large study published in the Journal of Clinical Oncology showed, even when patients are matched for baseline characteristics, those on a clinical trial vs not a clinical trial had superior overall survival at 5 years (95.0% vs 90.2%) and 7 years (90.0% vs 78.0%). Put simply, finding a trial may extend a person’s life.

Unfortunately a huge gulf exists between connecting eligible patients to trials, a problem that has only been exacerbated by the current COVID-19 pandemic. There is an urgent need to address this problem now.

METAvivor and Ciitizen are launching a new Clinical Trial Search Tool that makes exploring clinical trials easier and more accessible for stage 4 metastatic breast cancer patients. The tool allows patients to narrow in on applicable trials by answering a few questions about their condition. The tool then narrows potential trial options from the exhaustive set of all US based treatment trials. By streamlining multiple search queries into one report, we can ensure patients are aware of all their options. The user interface is clean, easy to use and accessible for patients with varied technical literacy.

The Clinical Trial Search Tool is accessible as part of METAvivor’s MBC Patient Resource and Education Portal (MBC PREP) and can be accessed by visiting Metavivor Clinical Trial Search

To learn more about METAvivor and Ciitizen’s partnership, please visit Metavivor Clinical Trial Search

ABOUT METAVIVOR

Metavivor Research and Support Inc. is an Annapolis-based, 501(c)(3), volunteer-led, non-profit organization founded by metastatic breast cancer (MBC) patients in 2009. The organization’s main focus is to fund critical research that will lead to advances in treatment options, quality of life and survival for patients diagnosed with MBC. Since 2009, Metavivor has awarded 106 research grants totaling $13.6 million. Metavivor is the only national organization with a peer-reviewed grant program aimed at exclusively funding MBC research, and 100% of all donations go to fund research.

Metavivor also raises awareness of MBC, provides support for people living with this disease, and offers opportunities for others to help make a difference for the metastatic community. Metavivor has gained a rapidly growing following within the breast cancer community and has become a leader in its field. For more information visit us at http://www.Metavivor.org, and follow us on Facebook, Twitter and Instagram @metavivor.

ABOUT CIITIZEN

Ciitizen is a leading consumer health technology company whose mission is to help patients get full control of their medical records so they can find better treatment options, participate in research and find clinical trials. As a patient-mediated platform, Ciitizen believes patients should have full control of directing the use of their data, which serves as one of the richest sources of real world evidence, unlocking new options for patients and the community. For more information, visit ciitizen.com or follow @ciitizen

Share article on social media or email: